World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
42013
World Ranking
6531
National Ranking
210

Piero Ruggenenti publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Piero Ruggenenti sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 412 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Piero Ruggenenti D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Piero Ruggenenti sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Piero Ruggenenti is affiliated with the Mario Negri Institute for Pharmacological Research in Italy. Their research primarily focuses on the field of Medicine, with particular emphasis on Nephrology, Infectious Diseases, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Pulmonary and Respiratory Medicine.

Their recent publications include:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis, 2021, The Lancet
  • Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis, 2021, The Lancet
  • Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial, 2020, The Lancet Diabetes & Endocrinology
  • Glomerular hyperfiltration, 2022, Nature Reviews Nephrology
  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure, 2023, Nature Medicine

The frequent co-authors who have collaborated extensively with Ruggenenti include Giuseppe Remuzzi, Annalisa Perna, Nadia Rubis, Tobia Peracchi, and Norberto Perico.

The main research topics covered in Ruggenenti's work encompass:

  • Renal Diseases and Glomerulopathies
  • COVID-19 Clinical Research Studies
  • Chronic Kidney Disease and Diabetes
  • Renal Transplantation Outcomes and Treatments
  • Blood Pressure and Hypertension Studies
  • Diabetes Treatment and Management
  • Long-Term Effects of COVID-19

Publications by Ruggenenti appear frequently in venues such as The Nephron journals, Journal of the American Society of Nephrology, The Lancet, Clinical Kidney Journal, and EClinicalMedicine.

Best Publications

  • Preventing microalbuminuria in type 2 diabetes.

    Piero Ruggenenti;Anna Fassi;Anelja Parvanova Ilieva;Simona Bruno

  • Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

    Piero Ruggenenti;Annalisa Perna;Giulia Gherardi;Giovanni Garini

  • Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

    Brad C. Astor;Kunihiro Matsushita;Ron T. Gansevoort;Marije Van Der Velde

  • Understanding the nature of renal disease progression

    Giuseppe Remuzzi;Piero Ruggenenti;Ariela Benigni

  • Nephropathy in Patients with Type 2 Diabetes

    Giuseppe Remuzzi;Arrigo Schieppati;Piero Ruggenenti

  • Progression, remission, regression of chronic renal diseases.

    Piero Ruggenenti;Arrigo Schieppati;Giuseppe Remuzzi

  • Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial

    Piero Ruggenenti;Annalisa Perna;Giulia Gherardi;Flavio Gaspari

  • Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

  • Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.

    Piero Ruggenenti;Annalisa Perna;Giacomina Loriga;Maria Ganeva

  • Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

    Piero Ruggenenti;Marina Noris;Giuseppe Remuzzi

  • The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

    Giuseppe Remuzzi;Norberto Perico;Manuel Macia;Piero Ruggenenti

  • Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

    Piero Ruggenenti;Annalisa Perna;Lidia Mosconi;Roberto Pisoni

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    Kazem Rahimi;Zeinab Bidel;Milad Nazarzadeh;Emma Copland

  • Long-Term Outcome of Renal Transplantation from Older Donors

    Giuseppe Remuzzi;Paolo Cravedi;Annalisa Perna;Borislav D. Dimitrov

  • Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

    Tazeen H Jafar;Paul C Stark;Christopher H Schmid;Marcia Landa

  • Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate.

    Flavio Gaspari;Norberto Perico;Piero Ruggenenti;Lidia Mosconi

  • Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria

    Giuseppe Remuzzi;Josep Grinyò;Piero Ruggenenti;Marco Beatini

  • Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease

    Aiko P J de Vries;Piero Ruggenenti;Xiong Z Ruan;Xiong Z Ruan;Manuel Praga

  • Rituximab for idiopathic membranous nephropathy

    Giuseppe Remuzzi;Carlos Chiurchiu;Mauro Abbate;Verusca Brusegan

  • ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

Frequent Co-Authors

Giuseppe Remuzzi
Giuseppe Remuzzi Mario Negri Institute for Pharmacological Research
Norberto Perico
Norberto Perico Mario Negri Institute for Pharmacological Research
Andrea Remuzzi
Andrea Remuzzi University of Bergamo
Marina Noris
Marina Noris Mario Negri Institute for Pharmacological Research
Peter Rossing
Peter Rossing University of Copenhagen
Dick de Zeeuw
Dick de Zeeuw University of Groningen
Ariela Benigni
Ariela Benigni Mario Negri Institute for Pharmacological Research
Barry M. Brenner
Barry M. Brenner Brigham and Women's Hospital
Gerjan Navis
Gerjan Navis University Medical Center Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees can be a smart way to begin or advance your medical career in the USA. For those looking for a quicker route to start working in the field, there are 6 month lpn program options that prepare you for entry-level nursing roles in less time.

If you’re seeking advanced practice or specialization, consider the fastest pmhnp program to become a psychiatric mental health nurse practitioner. These accelerated online programs allow you to continue working while developing new skills and expanding your career opportunities.

Another growing avenue is healthcare administration. Earning your MHA online gives you flexible options for learning, with the best online mha programs offering respected curriculums for future leaders. Cost is an important consideration; the cheapest online mha programs can help you manage expenses while pursuing a valuable credential.

These diverse online degrees are tailored for different career goals—whether direct patient care, mental health, or healthcare management—making them excellent pathways alongside or as alternatives to studying traditional Medicine in the USA.

Best Scientists Citing Piero Ruggenenti

Trending Scientists

Recently Published Articles